Novel multitargeted kinase inhibitor displays potent antitumor activity in preclinical cancer models April 28, 2009
AEZS-126, a new orally bioavailable PI3K inhibitor shows preclinical antitumor activity April 28, 2009
Selective inhibitors of anaplastic lymphoma kinase show in vitro and in vivo antitumor activity April 27, 2009
Second-generation FLT3 inhibitor developed as a candidate for acute myeloid leukemia therapy April 27, 2009
RSS